Nomura Raises Zhongji Innolight Target Price to RMB 1,375
N.R. Finch
Nomura raised its target price on Innolight (300308.SZ) from RMB 1,325 to RMB 1,375, maintaining a "buy" rating — but the upgrade is driven almost entirely by a higher valuation multiple, not higher near-term earnings. The real bet is on the next product cycle.
The target price rose only 3.8% — where did the upside come from?
Nomura trimmed its 2027 diluted EPS estimate from RMB 66.06 to RMB 65.47 — a slight cut. But it raised the P/E multiple from 20× to 21×. Multiply the two and you get the new target: RMB 1,375.
This means → this is not an "earnings upgrade" note. It is an "I'm willing to pay a richer multiple" note — Nomura's confidence upgrade shows up in valuation, not in profit.
The EPS dip reflects dilution from the upcoming H-share issuance — more shares splitting the same profit pool — already built into the model.
The outer-year forecasts rose more sharply — what is Nomura betting on?
Nomura raised 2026–2028 net profit estimates by 7%, 4%, and 10% respectively, and lifted gross margins by 1.5, 2.1, and 3.1 percentage points — the further out, the bigger the revision.
This means → Nomura is not repricing near-term delivery. It is repricing when next-generation products hit the revenue line — silicon photonics penetration (chip technology that uses light instead of electricity to move signals), 2.4T commercialization, and an improved NPO product mix.
But opex is rising too: 2027–2028 operating expenses were revised up 16% and 18% versus the old model, as R&D and new-product investment eat into part of the gross-margin gain. In plain terms = the company earns more but spends more, so net-profit leverage is smaller than the margin headline suggests.
Why is NPO the most critical variable in this report?
Nomura raised its 2027–2028 global NPO — near-package optics, mounting optical modules closer to the chip to boost transmission efficiency — shipment forecasts from 5 million / 20 million units to 8 million / 25 million units.
Innolight is expected to capture 40%–50% market share, contributing roughly 5%–6% of revenue. This means → NPO is small in revenue terms, but it is the signal that proves the company can break into the next-generation packaging architecture.
By contrast, CPO — co-packaged optics, embedding optical modules directly inside the chip package — is positioned as a far-end upside scenario. Nomura says it should not be mapped into current-period EPS.
What does the product-generation shipment roadmap look like?
800G is the volume base: growing from 40.8 million to 78 million units across 2026–2028, steady ramp.
1.6T is the revenue and earnings backbone: rising from 25.1 million to 126 million units, the largest absolute increase.
2.4T begins ramping in 2027; forecasts raised from 2 million / 5 million to 3 million / 8 million units. 3.2T starts at roughly 2 million units in 2028.
Nomura flags that certainty differs across generations: 1.6T is in mass-production validation; 2.4T and NPO are in 2027 customer-qualification and capacity-verification; 3.2T is a far-end option. In plain terms = the later the product, the more "expectation" baked into the forecast — they should not be priced at the same confidence level.
What does the H-share raise solve — and what does it not?
Innolight's H-share (3308.HK) base offering is 54.5 million shares at a maximum price of HKD 1,010, with an expected listing date of July 30. Net proceeds are approximately HKD 53 billion.
Allocation: roughly 35% to high-speed optical interconnect and NPO/CPO R&D, 30% to global capacity expansion, 15% to supply-chain M&A. This means → the funding gap is closed; the company now has the ammunition for both expansion and R&D.
But Nomura notes the real constraint is not capital — it is execution. Equipment, headcount, critical laser-diode supply, yield, and customer certification all need to replicate simultaneously across multiple production sites. That is the true bottleneck between today's 40 million units and the 2029 target of 90 million units.
Why does the cash-flow forecast deserve a separate look?
Nomura projects the cash conversion cycle to compress sharply — from 95.6 days in 2025 to 28.5 days in 2026 and 8.6 days in 2027.
This reflects a highly optimistic view on operational-efficiency gains. But if revenue surges while inventory, receivables, and operating cash flow fail to improve in lockstep, the profit anchor will face recalibration pressure.
In plain terms = the 2027–2028 ramp cadence matters more than the 2029 capacity target — it is the leading indicator that validates or breaks this optimistic model.
Content is for reference only, not financial advice.